Estrogen receptor ligands. Part 14: application of novel antagonist side chains to existing platforms

  • Bioorg Med Chem Lett. 2005 Dec 1;15(23):5124-8. doi: 10.1016/j.bmcl.2005.08.084.
Timothy A Blizzard  1 ,  Jerry D Morgan 2nd ,  Wanda Chan ,  Elizabeth T Birzin ,  Lee-Yuh Pai ,  Edward C Hayes ,  Carolyn A DaSilva ,  Ralph T Mosley ,  Yi Tien Yang ,  Susan P Rohrer ,  Frank Dininno ,  Milton L Hammond
Affiliations
  • 1. Merck Research Laboratories, RY800-B116, PO Box 2000, Rahway, NJ 07065, USA. [email protected]
PMID: 16203138 DOI: 10.1016/j.bmcl.2005.08.084
Abstract

Two novel side chains which had previously been found to enhance antagonist activity in the dihydrobenzoxathiin SERM series were applied to three existing platforms. The novel side chains did not improve the antagonist activity of the existing platforms.